A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia.

abstract：:The prevalence of tardive dyskinesia in a consecutive series of 69 patients with bipolar affective disorder admitted to a catchment area service was found to be 19%. Prevalence increased with age and was related to the age of onset of bipolar disorder and number of previous episodes. Patients with tardive dyskinesia w...

journal_title：International clinical psychopharmacology

authors： Hunt N,Silverstone T

更新日期：1991-04-01 00:00:00

abstract：:In an earlier study, we found a similar frequency of individuals with an abnormal correlation between serum leptin levels and body mass index (BMI) (outliers above or below the 95% confidence interval in the regression line) during treatment with antipsychotic drugs (n=301), other psychotropic drugs (n=65), and drug-f...

journal_title：International clinical psychopharmacology

authors： Marquina D,Peña R,Fernández E,Baptista T

更新日期：2011-05-01 00:00:00

abstract：:Human sexuality has three main roots: biological, motivational-affective-relational, and cognitive. Unfortunately, in women, the biological dimension is usually disregarded. Hormones are necessary, but not sufficient, factors to maintain a satisfying human libido. In women, oestrogens prime the central nervous system,...

journal_title：International clinical psychopharmacology

authors： Graziottin A

更新日期：1998-07-01 00:00:00

abstract：:The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia. In this double-blind, placebo-controlled study the dose of each drug was incre...

journal_title：International clinical psychopharmacology

authors： Hayashi T,Yokota N,Takahashi T,Tawara Y,Nishikawa T,Yano T,Furutani M,Fujikawa T,Horiguchi J,Yamawaki S

更新日期：1997-07-01 00:00:00

abstract：:The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

journal_title：International clinical psychopharmacology

authors： Landry P,Warnes H,Nielsen T,Montplaisir J

更新日期：1999-05-01 00:00:00

abstract：:We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between...

journal_title：International clinical psychopharmacology

authors： Pae CU,Wang SM,Han C,Bahk WM,Lee SJ,Patkar AA,Masand PS,Serretti A,Emsley R

更新日期：2017-09-01 00:00:00

abstract：:The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...

journal_title：International clinical psychopharmacology

authors： Zhang XY,Zhou DF,Cao LY,Zhang PY,Wu GY,Shen YC

更新日期：2001-11-01 00:00:00

abstract：:Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Mansuy L,Ruth AC,Li D,Gommoll C

更新日期：2014-01-01 00:00:00

abstract：:Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...

journal_title：International clinical psychopharmacology

authors： Berk M,Ichim L,Brook S

更新日期：1999-11-01 00:00:00

abstract：:The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Import...

journal_title：International clinical psychopharmacology

authors： Silver H

更新日期：2003-11-01 00:00:00

abstract：:Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

journal_title：International clinical psychopharmacology

authors： Phillips KA

更新日期：2006-05-01 00:00:00

abstract：:The aim of this study was to assess the response of social phobia (SP) symptoms to methylphenidate (MPH) treatment in children with attention deficit hyperactivity disorder (ADHD). Twenty-one ADHD patients with SP, aged between 8 and 18 years, received 12 weeks of MPH treatment. The severity of SP symptoms were assess...

journal_title：International clinical psychopharmacology

authors： Golubchik P,Sever J,Weizman A

更新日期：2014-07-01 00:00:00

abstract：:The present study aimed to identify the prescribing patterns of lithium or of lithium+valproate in 75 bipolar I outpatients in a manic or a mixed phase within a naturalistic setting. The differences between the two treatments and the correlation between serum lithium levels and response were also examined. The results...

journal_title：International clinical psychopharmacology

authors： Muti M,Del Grande C,Musetti L,Marazziti D,Pergentini I,Corsi M,Turri M,Umberto Corsini G,Dell'Osso L

更新日期：2013-11-01 00:00:00

abstract：:This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression. This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS). The major determinant of the symptoms may have been dopami...

journal_title：International clinical psychopharmacology

authors： Miyaoka H,Kamijima K

更新日期：1995-11-01 00:00:00

abstract：:Long-term treatment with benzodiazepines (BZD) should be avoided in dementia patients because of an increased risk of adverse events. We evaluated how continuously dementia patients were prescribed BZD over 12 months. For this observational study, we used claims data from a large German public sickness fund for 2014 a...

journal_title：International clinical psychopharmacology

authors： Hessmann P,Jan Zeidler,Neubauer S,Abdel-Hamid M,Stahmeyer J,Eberhard S,Wolff-Menzler C,Wiltfang J,Kis B

更新日期：2018-09-01 00:00:00

abstract：:In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonst...

journal_title：International clinical psychopharmacology

authors： Barbui C,Garattini S

更新日期：1999-03-01 00:00:00

abstract：:Hematological indices were measured in 8 patients with bipolar disorder during carbamazepine and carbamazepine-lithium combination treatment. Carbamazepine treatment was associated with limited reductions in white blood cell indices. Combined lithium-carbamazepine treatment reversed the reductions in total white cell ...

journal_title：International clinical psychopharmacology

authors： Joffe RT

更新日期：1988-01-01 00:00:00

abstract：:It has been suggested that dopamine/serotonin (5-HT) imbalance, with relative enhancement of serotonergic activity, might be one of the possible pathophysiological mechanisms underlying neuroleptic-induced akathisia. On the basis of preclinical data, which imply that the partial 5-HT1A agonist buspirone possesses anti...

journal_title：International clinical psychopharmacology

authors： Poyurovsky M,Weizman A

更新日期：1997-09-01 00:00:00

abstract：:Thirty healthy subjects 12 males and 18 females were given the acetylcholinesterase inhibitor pyridostigmine (120 mg) orally. The growth hormone (GH) response was measured as the maximum GH level post-pyridostigmine relative to baseline. Twenty-six subjects increased their GH level in response to pyridostigmine. Respo...

journal_title：International clinical psychopharmacology

authors： Lucey JV,O'Keane V,O'Flynn K,Clare AW,Dinan TG

更新日期：1991-07-01 00:00:00

abstract：:A review of published evidence of superior efficacy of a particular antidepressant in major depressive disorder may assist clinicians in making considered treatment choices. To identify such candidates, an international group of experts met to assess published evidence (identified through searches in Medline and Embas...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Baldwin DS,Blier P,Fineberg NA,Kasper S,Lader M,Lam RW,Lépine JP,Möller HJ,Nutt DJ,Rouillon F,Schatzberg AF,Thase ME

更新日期：2007-11-01 00:00:00

abstract：:A new short-acting thieno-diazepine compound, brotizolam, has been compared to nitrazepam in a double-blind trial. Following an initial 3-day control period with no treatment, insomniac patients were allocated to 2 weeks treatment with one or the other drug according to random selection. This was then followed by a fu...

journal_title：International clinical psychopharmacology

authors： Wheatley D

更新日期：1986-01-01 00:00:00

abstract：:Good evidence now exists for a therapeutic action of carbamazepine (CBZ) both in acute mania and in the prophylaxis of manic depression. Comparison with other existing therapies and incidence of adverse effects in psychiatric patients also deserve more clinical research. This paper reviews these clinical issues and th...

journal_title：International clinical psychopharmacology

authors： Elphick M

更新日期：1988-07-01 00:00:00

abstract：:We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...

journal_title：International clinical psychopharmacology

authors： Velayudhan L,Kirchner V

更新日期：2005-03-01 00:00:00

abstract：:The effects of an abrupt interruption of agomelatine, a new melatonergic/serotonergic antidepressant, were explored in a double-blind, placebo-controlled study. Paroxetine was used as active control. After 12 weeks of double-blind treatment with agomelatine 25 mg/day or paroxetine 20 mg/day, sustained remitted depress...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Kennedy SH,Burrows GD,Lejoyeux M,Hindmarch I

更新日期：2004-09-01 00:00:00

abstract：:The introduction of second generation antipsychotics (SGA) represents a major advance in the treatment of schizophrenia. Concerns about the metabolic and cardiovascular adverse effects of the SGA have been widely disseminated. The benefits and risks of these drugs have been studied with a focus on particular organ sys...

journal_title：International clinical psychopharmacology

authors： Barak Y,Swartz M,Plopsky I

更新日期：2005-11-01 00:00:00

abstract：:The sedative properties of two doses (50 and 150 mg) of a benzodiazepine partial agonist, PK 8165 (pipequaline), were compared to diazepam 10 mg and placebo in 12 normal volunteers. The assessment, performed before drug intake and 2 and 5 hours after drug intake, included a battery of visual analogue scales and standa...

journal_title：International clinical psychopharmacology

authors： von Frenckell R,Ansseau M,Bonnet D

更新日期：1986-01-01 00:00:00

abstract：:Major depressive disorder (MDD) is currently the second most common cause of disability worldwide. Current treatment of MDD with selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors is limited by efficacy and tolerability issues, highlighting the unmet need in the treatment of patien...

journal_title：International clinical psychopharmacology

authors： Montgomery SA

更新日期：2008-03-01 00:00:00

abstract：:A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder. Two different doses of medication were given for 4 weeks. Effectiveness was measured by improvements in the Hamilton Rating Scale for Depression, a self-rating ...

journal_title：International clinical psychopharmacology

authors： Lensch K,Fuchs G,Böning J,Milech U

更新日期：1987-04-01 00:00:00

abstract：:Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

journal_title：International clinical psychopharmacology

authors： Joyce PR

更新日期：1988-04-01 00:00:00

abstract：:The tricyclic antidepressants (TCAs) are still considered as first-line treatment for depression, despite the availability of the selective serotonin reuptake inhibitors (SSRIs). This paper considers the current situation in reverse by assuming that only the SSRIs, in particular fluvoxamine, are available and the TCAs...

journal_title：International clinical psychopharmacology

authors： Ashford JJ

更新日期：1995-01-01 00:00:00